[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complex-renal-cyst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complex-renal-cyst":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100405378","surveillance-of-complex-renal-cysts---the-socratic-study-100405378",false,"NCT04558593","Surveillance of Complex Renal Cysts - The SOCRATIC Study","SOCRATIC","Inclusion Criteria:\n\n* 18 years old and older;\n* diagnosed with a Bosniak III or IV cyst (classification 2019);\n* size of cystic component ≤7cm;\n* cyst wall\u002Fseptum nodule (obtuse margin of protrusion) \\\u003C10mm (perpendicular axis) or nodular\u002Fsolid component ≤2 cm in any axis;\n* life expectancy \\>5 years (by physician's estimate);\n* new diagnosis ≤ 12 months from accrual date;\n* currently asymptomatic from the disease;\n* deemed fit enough for surgery;\n* willingness and ability to complete questionnaires in either French or English;\n* able and willing to provide informed consent\n\nExclusion Criteria:\n\n* history of a hereditary renal cancer syndrome;\n* presence of polycystic kidney disease;\n* any prior history of RCC;\n* received systemic therapy for another malignancy within the 12 months prior to accrual;\n* uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction\u002Funstable angina within 6 months that would predispose to immediate surgical therapy;\n* metastatic disease or evidence of vascular or nodal disease;\n* unwillingness to undergo monitoring and imaging studies;\n* any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate \\\u003C30min\u002FmL)","ALL","18 Years",{"count":19,"type":20},330,"ESTIMATED","OBSERVATIONAL","One third of individuals aged \\>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III\u002FIV cysts.\n\nThis is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.",[24],"Complex Renal Cyst",[26,27,28,29,30,31,32,33],"renal cyst","complex cyst","Bosniak III","Bosniak IV","renal masses","active surveillance","monitoring","surgery","RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-01","ACTUAL",{"date":40,"type":38},"2021-02-02",{"date":42,"type":20},"2031-09-20",{"name":44,"class":45},"Université de Sherbrooke","OTHER",18,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100589038","phase-2-68ga-nym096-pet-ct-for-the-detection-of-ccrcc-in-presurgical-patients-with-complex-cystic-renal-leision-100589038","NCT06949215","68Ga-NYM096 PET\u002F CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision","68Ga-NYM096 PET\u002F CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Complex Cystic Renal Leision","NYCRCCL","Inclusion Criteria:\n\n1. Age ≥ 18 y\n2. Presence of complex renal cyst (Bosniak category II or higher)\n3. Scheduled for surgical resection of renal mass (partial or total nephrectomy, open, laparoscopic, or robot-assisted technique)\n4. Expected survival of at least 3 months\n5. ECOG ≤ 2\n6. Written informed consent provided for participation in the trial\n7. In the opinion of investigator, willing and able to comply with required study procedures.\n\nExclusion Criteria:\n\n1. On VEGF TKI treatment less than 1 week before 68Ga-NYM096 PET\u002FCT. TKI is known to affect girentuximab binding in patients with ccRCC and is expected to have the same effect on 68Ga-NYM096. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NYM096 PET\u002FCT is required.\n2. Intercurrent medical condition that renders the patient ineligible for surgery.\n3. Pregnancy or breastfeeding.\n4. Severe claustrophobia.",{"count":56,"type":20},70,"INTERVENTIONAL",[59],"PHASE2","This is a prospective, single-center, single-arm, diagnostic phase 2 study aimed at evaluating the sensitivity and specificity of 68Ga-NYM096 PET\u002FCT in detecting clear cell renal cell carcinoma (ccRCC) in patients with complex renal cysts who are scheduled for surgical resection. The study will use histopathological diagnosis as the reference standard to assess the diagnostic accuracy of 68Ga-NYM096 PET\u002FCT in identifying ccRCC within operable complex renal cystic lesion. The findings will provide critical insights into the performance of 68Ga-NYM096 PET\u002FCT as a non-invasive imaging tool for the preoperative detection of ccRCC in this patient population.",[62,24],"ccRCC",[64,65,66],"PET\u002FCT","complex renal cyst","68Ga-NYM096","2026-05-21",{"date":69,"type":38},"2026-05-26",{"date":71,"type":38},"2025-05-01",{"date":73,"type":20},"2027-07-01",{"name":75,"class":45},"Peking Union Medical College Hospital",1]